Core Insights - Immunome, Inc. is focused on developing first-in-class and best-in-class targeted cancer therapies [1] - On October 1, 2025, the Compensation Committee granted inducement awards consisting of non-statutory stock options [1] - A total of 69,000 shares of common stock were awarded to 5 new employees under the Company's 2024 Inducement [1]